Heavy Bupivacaine in Peribulbar Block
Launched by CAIRO UNIVERSITY · Oct 13, 2017
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
Peribulbar anesthesia is widely practiced now as a safe local block for cataract eye surgeries. However, the limited duration of these blocks was shown to be the main problem encountered intra-operatively. Therefore, additional top-up doses are usually needed to continue the operation. Many kinds of research tried to introduce solutions in order to prolong the duration of the local anesthetics used. Many researchers tried different volumes, doses and adjuvant to local anesthetics, and studied their effects There are many studies that evaluated the effect of baricity of local anesthetic on t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with American Society of Anesthesiology (ASA) I or II.
- • 30-80 years old
- • Patients scheduled for elective unilateral posterior segment surgeries.
- Exclusion Criteria:
- • Patient's refusal.
- • orbital deformity
- • axial length( \>28 mm )
- • increased intraocular pressure, or if they were blind in the contralateral eye, international normalized ratio (INR) \> 1.5
- • allergy to local anesthetics, mentally retarded patients
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Giza, Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials